Role of Dicer as a prognostic predictor for survival in cancer patients: a systematic review with a meta-analysis.
Role of Dicer as a prognostic predictor for survival in cancer patients: a systematic review with a meta-analysis.
复制标题
Dicer 作为癌症患者生存预后预测因子的作用：荟萃分析的系统评价。
DOI：
10.18632/oncotarget.12183
复制
发表时间：
2016-11-08
期刊：
影响因子：
--
通讯作者：
Chen G
中科院分区：
文献类型：
--
作者：
Shan W;Sun C;Zhou B;Guo E;Lu H;Xia M;Li K;Weng D;Lin X;Meng L;Ma D;Chen G
Dicer在癌症患者预后中的作用仍有争议。本系统综述旨在评估Dicer在不同类型癌症中作为预后预测因子的影响。如果研究发表了Dicer表达水平的独立评估以及与癌症预后的相关性，则被选为候选研究。本meta分析采用随机效应模型。采用q统计量评价研究间异质性，P < 0.10为差异有统计学意义。发表偏倚采用漏斗图和Begg’s和Egger’s检验。P < 0.05为差异有统计学意义。44篇文章中有24篇揭示了低Dicer状态作为不良预后的预测因子。总生存期（OS）的综合结果表明，低Dicer表达水平导致临床预后差，IHC亚组和RT-PCR法的结果相同。无进展生存期（PFS）的总体分析结果与OS相同，两个亚组按实验室方法划分均为阳性结果。肿瘤类型亚组分析显示，低肿瘤水平与卵巢癌（HR = 1.93, 95% CI: 1.19-3.15）、耳鼻喉肿瘤（HR = 2.39, 95% CI: 1.70-3.36）、血液系统恶性肿瘤（HR = 2.45, 95% CI: 1.69-3.56）和神经母细胞瘤（HR = 4.03, 95% CI: 1.91-8.50）预后不良相关。卵巢癌、耳鼻喉肿瘤和恶性肿瘤的预后较差。需要更多同质、高质量的研究进一步证实我们的结论，使Dicer在临床应用中成为一个有用的参数。
The role of Dicer in the prognosis of cancer patients remains controversial. This systematic review is attempted to assess the influence of Dicer as a prognostic predictor for survival in diverse types of cancers. Studies were selected as candidates if they published an independent evaluation of Dicer expression level together with the correlation with prognosis in cancers. Random-effect model was applied in this meta-analysis. Heterogeneity between studies was assessed by Q-statistic with P < 0.10 to be statistically significant. Publication bias was investigated using funnel plot and test with Begg's and Egger's test. P < 0.05 was regarded as statistically significant. 24 of 44 articles revealed low Dicer status as a predictor of poor prognosis. The aggregate result of overall survival (OS) indicated that low Dicer expression level resulted in poor clinical outcomes, and subgroup of IHC and RT-PCR method both revealed the same result. Overall analysis of progression-free survival (PFS) showed the same result as OS, and both the two subgroups divided by laboratory method revealed positive results. Subgroup analysis by tumor types showed low dicer levels were associated with poor prognosis in ovarian cancer (HR = 1.93, 95% CI: 1.19-3.15), otorhinolaryngological tumors (HR = 2.39, 95% CI: 1.70-3.36), hematological malignancies (HR = 2.45, 95% CI: 1.69-3.56) and neuroblastoma (HR = 4.03, 95% CI: 1.91-8.50). Low Dicer status was associated with poor prognosis in ovarian cancer, otorhinolaryngological tumors and ematological malignancies. More homogeneous studies with high quality are needed to further confirm our conclusion and make Dicer a useful parameter in clinical application.